Pagturok ng magkaibang COVID-19 vaccines kinuwestiyon ni Sen. de Lima

By Jan Escosio May 10, 2021 - 11:12 AM

PNP photo

Duda si Senator Leila de Lima na kapritso at hindi siyensya ang nagtulak sa Department of Health (DOH) para magbalangkas na ng guidelines para sa ‘mixed-use vaccinations.

Sinabi ni de Lima na may mga isinasagawa ng trials sa ibang mga bansa para sa pagtuturok ng magkaibang brand ng COVID 19 vaccines, ngunit wala pang konkretong ulat ukol sa kaligtasan at bisa ng ganitong diskarte.

Ang hakbang anya ng kagawaran ay bunga ng pambabatikos kay Pangulong Duterte sa pagpapaturok niya ng Sinopharm vaccine na wala pang emergency use authorization (EUA) mula sa Food and Drug Administration (FDA).

Kasunod nito, ipinag-utos ni Pangulong Duterte ang pagsosoli ng natitirang Sinopharm vaccines sa China bagamat kailangan pa niya ang second dose ng bakuna.

Una na rin inihayag ng Malakanyang na hindi kasama sa mga isosoling bakuna ang second dose ng Punong Ehekutibo.

“They (DOH) need to be reminded that their mandate is to promote and safeguard public health and not protect Duterte’s “feelings”. If Duterte wishes to withdraw the Sinopharm vaccine and experiment with a different 2nd dose, then by all means let him. Why is there a need to impose this as a national policy?” tanong ni de  Lima.

Diin pa nito, ibang usapan na kung pag-eeksperimentuhan ang taumbayan para lamang bigyan katuwiran ang paggamit ni Pangulong Duterte ng smuggled na bakuna.

 

TAGS: COVID-19 vaccines, doh, Rodrigo Duterte, Senator Leila De Lima, COVID-19 vaccines, doh, Rodrigo Duterte, Senator Leila De Lima

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.